Business Description
Concord Drugs Ltd
ISIN : INE858L01010
Compare
Compare
Traded in other countries / regions
538965.India IPO Date
2015-02-23Description
Concord Drugs Ltd is an India based pharmaceutical company. The principal activity of the company is to manufacture licensed drugs based on the formulations approved. Its product portfolio includes Pharmaceutical Ready to fill Pellets, MUPS ((Multiple Unit Pellets System); Tissue Bio Adhesive; Injectables (Small Volume Parenterals); Capsules; Liquid Orals (Syrups & Suspensions); Dry Syrups (Powder) and Hand Sanitizers.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.02 | |||||
| Equity-to-Asset | 0.46 | |||||
| Debt-to-Equity | 0.56 | |||||
| Debt-to-EBITDA | 7.1 | |||||
| Interest Coverage | 0.66 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 1.74 | |||||
| Beneish M-Score | -2.29 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -8.5 | |||||
| 3-Year EBITDA Growth Rate | -20.3 | |||||
| 3-Year EPS without NRI Growth Rate | -2.7 | |||||
| 3-Year FCF Growth Rate | 62.3 | |||||
| 3-Year Book Growth Rate | 3.4 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.16 | |||||
| 9-Day RSI | 42.52 | |||||
| 14-Day RSI | 43.9 | |||||
| 6-1 Month Momentum % | -8.94 | |||||
| 12-1 Month Momentum % | 1.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.79 | |||||
| Quick Ratio | 1.06 | |||||
| Cash Ratio | 0.01 | |||||
| Days Inventory | 197.91 | |||||
| Days Sales Outstanding | 170.92 | |||||
| Days Payable | 67.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.6 | |||||
| Shareholder Yield % | -3.25 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 18.92 | |||||
| Operating Margin % | 2.42 | |||||
| Net Margin % | -0.97 | |||||
| FCF Margin % | -0.43 | |||||
| ROE % | -1.52 | |||||
| ROA % | -0.8 | |||||
| ROIC % | 1.69 | |||||
| ROC (Joel Greenblatt) % | 2.32 | |||||
| ROCE % | 3.17 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shiller PE Ratio | 20.55 | |||||
| PS Ratio | 0.67 | |||||
| PB Ratio | 1.05 | |||||
| Price-to-Tangible-Book | 1.04 | |||||
| Price-to-Operating-Cash-Flow | 44.64 | |||||
| EV-to-EBIT | 44.33 | |||||
| EV-to-EBITDA | 20.15 | |||||
| EV-to-Revenue | 1.03 | |||||
| EV-to-FCF | -240.51 | |||||
| Price-to-Projected-FCF | 1.17 | |||||
| Price-to-Median-PS-Value | 1.36 | |||||
| Price-to-Net-Current-Asset-Value | 1.75 | |||||
| Earnings Yield (Greenblatt) % | 2.25 | |||||
| FCF Yield % | -0.64 | |||||
| Forward Rate of Return (Yacktman) % | -1.86 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Concord Drugs Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 524.797 | ||
| EPS (TTM) (₹) | -0.51 | ||
| Beta | 1.12 | ||
| Volatility % | 84.85 | ||
| 14-Day RSI | 43.9 | ||
| 14-Day ATR (₹) | 2.168795 | ||
| 20-Day SMA (₹) | 36.665 | ||
| 12-1 Month Momentum % | 1.02 | ||
| 52-Week Range (₹) | 30.59 - 61.5 | ||
| Shares Outstanding (Mil) | 10 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Concord Drugs Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Concord Drugs Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Concord Drugs Ltd Frequently Asked Questions
What is Concord Drugs Ltd(BOM:538965)'s stock price today?
The current price of BOM:538965 is ₹35.35. The 52 week high of BOM:538965 is ₹61.50 and 52 week low is ₹30.59.
When is next earnings date of Concord Drugs Ltd(BOM:538965)?
The next earnings date of Concord Drugs Ltd(BOM:538965) is .
Does Concord Drugs Ltd(BOM:538965) pay dividends? If so, how much?
Concord Drugs Ltd(BOM:538965) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers